Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific equity transaction for Mr. S M Bicknell on May 6, 2014, involving the exercise of nil-priced options under the GSK Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports the execution of a share-based compensation plan.
Important Facts for Investors
- Transaction Type: Exercise of nil-priced options by a PDMR (Mr. S M Bicknell).
- Shares Involved: Options over 7,912 shares and 3,149 shares were exercised.
- Net Settlement: The company delivered a net of tax value in shares totaling 5,862 shares.
- Plan Details: The options were granted on February 24, 2011, and vested on February 24, 2014.
- Notification Date: The transaction was notified to the company and the PDMR on May 7, 2014.